Top

Published in:

01-04-2010 | Clinical trial

The contralateral synchronous breast carcinoma: a comparison of histology, localization, and magnetic resonance imaging characteristics with the primary index cancer

Authors: Diane M. Renz, Joachim Böttcher, Pascal A. T. Baltzer, Matthias Dietzel, Tibor Vag, Mieczyslaw Gajda, Oumar Camara, Ingo B. Runnebaum, Werner A. Kaiser

Published in: Breast Cancer Research and Treatment | Issue 2/2010

Abstract

Women with unilateral breast carcinoma reveal an increased risk of suffering from malignancies in the contralateral breast. There is a controversy about the existence of bilateral phenotypic similarities. The aim of this investigation was to compare histologic findings, magnetic resonance imaging (MRI) parameters, and tumor localizations of synchronous bilateral carcinomas. MRI revealed in 42 of 875 women (4.8%) with primary index carcinomas a contralateral malignancy. Twenty-two of the 42 contralateral carcinomas could only be detected by MRI, not by clinical examination, X-ray mammography, or ultrasonography. In 875 patients, MRI therefore identified 22 (2.5%) otherwise occult contralateral cancers. To evaluate bilateral MRI similarities, multiple dynamic and morphologic parameters were evaluated. Of 42 bilateral cancer pairs, histologic tumor type was identical in 54.8% (correlation analysis, P < 0.05). Estrogen receptor status was simultaneously positive or negative in 86.2% (P < 0.01), progesterone receptor status in 79.3% (P < 0.05), expression of human epidermal growth factor receptor 2 in 76.2% (P < 0.05). In 75.8%, initial signal increase, and in 63.6%, postinitial curve types were bilaterally congruent on MRI (P < 0.05). Detected masses showed bilaterally similar T2-signal intensity in 81.8% (P < 0.001). Similar shape and margin of tumor masses and occurrence of non-mass-like enhancement were also frequently observed in both breasts (P < 0.05). The main tumor quadrant was the same in 61.9%, the main localization (retromamillar, central, or dorsal) in 66.7% (P < 0.01). Contralateral carcinomas frequently present similar histologic findings, tumor localizations and MRI characteristics reflecting analogies of tumor neoangiogenesis, histopathologic components, and infiltration in the surrounding stroma. Bilateral synchronous carcinomas may represent on each site distinct, but similar biologic entities, due to analogous influences of tumor developments.

Hungness ES, Safa M, Shaughnessy EA, Aron BS, Gazder PA, Hawkins HH, Lower EE, Seeskin C, Yassin RS, Hasselgren PO (2000) Bilateral synchronous breast cancer: mode of detection and comparison of histologic features between the two breasts. Surgery 128:702–707. doi:10.1067/msy.2000.108780 CrossRefPubMed

Jobsen JJ, van der Palen J, Ong F, Meerwaldt JH (2003) Synchronous, bilateral breast cancer: prognostic value and incidence. Breast 12:83–88. doi:10.1016/S0960-9776(02)00278-3 CrossRefPubMed

Heron DE, Komarnicky LT, Hyslop T, Schwartz GF, Mansfield CM (2000) Bilateral breast carcinoma: risk factors and outcomes for patients with synchronous and metachronous disease. Cancer 88:2739–2750. doi:10.1002/1097-0142(20000615)88 CrossRefPubMed

Kollias J, Ellis IO, Elston CW, Blamey RW (2001) Prognostic significance of synchronous and metachronous bilateral breast cancer. World J Surg 25:1117–1124PubMed

Chaudary MA, Millis RR, Hoskins EO, Halder M, Bulbrook RD, Cuzick J, Hayward JL (1984) Bilateral primary breast cancer: a prospective study of disease incidence. Br J Surg 71:711–714CrossRefPubMed

Kollias J, Pinder SE, Denley HE, Ellis IO, Wencyk P, Bell JA, Elston CW, Blamey RW (2004) Phenotypic similarities in bilateral breast cancer. Breast Cancer Res Treat 85:255–261. doi:10.1023/B:BREA.0000025421.00599.b7 CrossRefPubMed

Poggi MM, Danforth DN, Sciuto LC, Smith SL, Steinberg SM, Liewehr DJ, Menard C, Lippman ME, Lichter AS, Altemus RM (2003) Eighteen-year results in the treatment of early breast carcinoma with mastectomy versus breast conservation therapy: the National Cancer Institute randomized trial. Cancer 98:697–702. doi:10.1002/cncr.11580 CrossRefPubMed

Takahashi H, Watanabe K, Takahashi M, Taguchi K, Sasaki F, Todo S (2005) The impact of bilateral breast cancer on the prognosis of breast cancer: a comparative study with unilateral breast cancer. Breast Cancer 12:196–202. doi:10.2325/jbcs.12.196 CrossRefPubMed

Kuhl CK (2007) Current status of breast MR imaging. Part 2. Clinical applications. Radiology 244:672–691. doi:10.1148/radiol.2443051661 CrossRefPubMed

10.

Orel SG, Schnall MD (2001) MR imaging of the breast for the detection, diagnosis, and staging of breast cancer. Radiology 220:13–30PubMed

11.

Kaiser WA, Zeitler E (1989) MR imaging of the breast: fast imaging sequences with and without Gd-DTPA. Preliminary observations. Radiology 170:681–686PubMed

12.

Boetes C, Mus RD, Holland R, Barentsz JO, Strijk SP, Wobbes T, Hendriks JH, Ruys SH (1995) Breast tumors: comparative accuracy of MR imaging relative to mammography and US for demonstrating extent. Radiology 197:743–747PubMed

13.

Fischer U, Kopka L, Grabbe E (1999) Breast carcinoma: effect of preoperative contrast-enhanced MR imaging on the therapeutic approach. Radiology 213:881–888PubMed

14.

Uematsu T, Yuen S, Kasami M, Uchida Y (2009) Comparison of magnetic resonance imaging, multidetector row computed tomography, ultrasonography, and mammography for tumor extension of breast cancer. Breast Cancer Res Treat 112:461–474. doi:10.1007/s10549-008-9890-y CrossRef

15.

Sardanelli F, Giuseppetti GM, Panizza P, Bazzocchi M, Fausto A, Simonetti G, Lattanzio V, Del Maschio A (2004) Sensitivity of MRI versus mammography for detecting foci of multifocal, multicentric breast cancer in fatty and dense breasts using the whole-breast pathologic examination as a gold standard. AJR Am J Roentgenol 183:1149–1157PubMed

16.

Braun M, Pölcher M, Schrading S, Zivanovic O, Kowalski T, Flucke U, Leutner C, Park-Simon TW, Rudlowski C, Kuhn W, Kuhl CK (2009) Influence of preoperative MRI on the surgical management of patients with operable breast cancer. Breast Cancer Res Treat 111:179–187. doi:10.1007/s10549-007-9767-5 CrossRef

17.

Lee SG, Orel SG, Woo IJ, Cruz-Jove E, Putt ME, Solin LJ, Czerniecki BJ, Schnall MD (2003) MR imaging screening of the contralateral breast in patients with newly diagnosed breast cancer: preliminary results. Radiology 226:773–778. doi:10.1148/radiol.2263020041 CrossRefPubMed

18.

Liberman L, Morris EA, Kim CM, Kaplan JB, Abramson AF, Menell JH, Van Zee KJ, Dershaw DD (2003) MR imaging findings in the contralateral breast of women with recently diagnosed breast cancer. AJR Am J Roentgenol 180:333–341PubMed

19.

Slanetz PJ, Edmister WB, Yeh ED, Talele AC, Kopans DB (2002) Occult contralateral breast carcinoma incidentally detected by breast magnetic resonance imaging. Breast J 8:145–148. doi:10.1046/j.1524-4741.2002.08304 CrossRefPubMed

20.

Rieber A, Merkle E, Böhm W, Brambs HJ, Tomczak R (1997) MRI of histologically confirmed mammary carcinoma: clinical relevance of diagnostic procedures for detection of multifocal or contralateral secondary carcinoma. J Comput Assist Tomogr 21:773–779CrossRefPubMed

21.

Lehman CD, Gatsonis C, Kuhl CK, Hendrick RE, Pisano ED, Hanna L, Peacock S, Smazal SF, Maki DD, Julian TB, DePeri ER, Bluemke DA, Schnall MD (2007) MRI evaluation of the contralateral breast in women with recently diagnosed breast cancer. N Engl J Med 365:1295–1303CrossRef

22.

Dawson PJ, Maloney T, Gimotty P, Juneau P, Ownby H, Wolman SR (1991) Bilateral breast cancer: one disease or two? Breast Cancer Res Treat 19:233–244CrossRefPubMed

23.

Brennan ME, Houssami N, Lord S, Macaskill P, Irwig L, Dixon JM, Warren RM, Ciatto S (2009) Magnetic resonance imaging screening of the contralateral breast in women with newly diagnosed breast cancer: systematic review and meta-analysis of incremental cancer detection and impact on surgical management. J Clin Oncol 27:5640–5649. doi:10.1200/JCO.2008.21.5756 CrossRefPubMed

24.

Lou L, Cong XL, Yu GF, Li JC, Ma YX (2007) US findings of bilateral primary breast cancer: retrospective study. Eur J Radiol 61:154–157. doi:10.1016/j.ejrad.2006.08.022 CrossRefPubMed

25.

Kim MJ, Kim EK, Kwak JY, Park BW, Kim SI, Oh KK (2008) Bilateral synchronous breast cancer in an Asian population: mammographic and sonographic characteristics, detection methods, and staging. AJR Am J Roentgenol 190:208–213. doi:10.2214/AJR.07.2714 CrossRefPubMed

26.

Kuhl CK, Mielcareck P, Klaschik S, Leutner C, Wardelmann E, Gieseke J, Schild HH (1999) Dynamic breast MR imaging: are signal intensity time course data useful for differential diagnosis of enhancing lesions? Radiology 211:101–110PubMed

27.

Malich A, Fischer DR, Wurdinger S, Böttcher J, Marx C, Facius M, Kaiser WA (2005) Potential MRI interpretation model: differentiation of benign from malignant breast masses. AJR Am J Roentgenol 185:964–970. doi:10.2214/AJR.04.1073 CrossRefPubMed

28.

Baum F, Fischer U, Vosshenrich R, Grabbe E (2002) Classification of hypervascularized lesions in CE MR imaging of the breast. Eur Radiol 12:1087–1092. doi:10.1007/s00330-001-1213-1 CrossRefPubMed

29.

American College of Radiology (2003) Breast imaging reporting and data system (BI-RADS) atlas, 4th edn. American College of Radiology, Reston, VA

30.

Kaiser WA (2007) Signs in MR-mammography. Springer, Berlin, Heidelberg, New York

31.

Renz DM, Baltzer PAT, Böttcher J, Thaher F, Gajda M, Camara O, Runnebaum IB, Kaiser WA (2008) Magnetic resonance imaging of inflammatory breast carcinoma and acute mastitis. A comparative study. Eur Radiol 18:2370–2380. doi:10.1007/s00330-008-1029-3 CrossRefPubMed

32.

Elston CW, Ellis IO (1991) Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19:403–410CrossRefPubMed

33.

Pengel KE, Loo CE, Teertstra HJ, Muller SH, Wesseling J, Peterse JL, Bartelink H, Rutgers EJ, Gilhuijs KG (2009) The impact of preoperative MRI on breast-conserving surgery of invasive cancer: a comparative cohort study. Breast Cancer Res Treat 116:161–169. doi:10.1007/s10549-008-0182-3 CrossRefPubMed

34.

Pediconi F, Catalano C, Roselli A, Padula S, Altomari F, Moriconi E, Pronio AM, Kirchin MA, Passariello R (2007) Contrast-enhanced MR mammography for evaluation of the contralateral breast in patients with diagnosed unilateral breast cancer or high-risk lesions. Radiology 243:670–680. doi:10.1148/radiol.2433060838 CrossRefPubMed

35.

Collins LC, Tamimi RM, Baer HJ, Connolly JL, Colditz GA, Schnitt SJ (2005) Outcome of patients with ductal carcinoma in situ untreated after diagnostic biopsy: results from the Nurses′ Health Study. Cancer 103:1778–1784. doi:10.1002/cncr.20979 CrossRefPubMed

36.

Sterns EE, Fletcher WA (1991) Bilateral cancer of the breast: a review of clinical, histologic, and immunohistologic characteristics. Surgery 110:617–622PubMed

37.

Roubidoux MA, Lai NE, Paramagul C, Joynt LK, Helvie MA (1996) Mammographic appearance of cancer in the opposite breast: comparison with the first cancer. AJR Am J Roentgenol 166:29–31PubMed

38.

Murphy TJ, Conant EF, Hanau CA, Ehrlich SM, Feig SA (1995) Bilateral breast carcinoma: mammographic and histologic correlation. Radiology 195:617–621PubMed

39.

Degani H, Chetrit-Dadiani M, Bogin L, Furman-Haran E (2003) Magnetic resonance imaging of tumor vasculature. Thromb Haemost 89:25–33PubMed

40.

Buadu LD, Murakami J, Murayama S, Hashiguchi N, Sakai S, Masuda K, Toyoshima S, Kuroki S, Ohno S (1996) Breast lesions: correlation of contrast medium enhancement patterns on MR images with histopathologic findings and tumor angiogenesis. Radiology 200:639–649PubMed

41.

Sherif H, Mahfouz AE, Oellinger H, Hadijuana J, Blohmer JU, Taupitz M, Felix R, Hamm B (1997) Peripheral washout sign on contrast-enhanced MR images of the breast. Radiology 205:209–213PubMed

42.

Tse GM, Chaiwun B, Wong KT, Yeung DK, Pang AL, Tang AP, Cheung HS (2007) Magnetic resonance imaging of breast lesions—a pathologic correlation. Breast Cancer Res Treat 103:1–10. doi:10.1007/s10549-006-9352-3 CrossRefPubMed

43.

Fischer DR, Baltzer P, Malich A, Wurdinger S, Freesmeyer MG, Marx C, Kaiser WA (2004) Is the “blooming sign” a promising additional tool to determine malignancy in MR mammography? Eur Radiol 14:394–401. doi:10.1007/s00330-003-2055-9 CrossRefPubMed

44.

Dawson LA, Chow E, Goss PE (1998) Evolving perspectives in contralateral breast cancer. Eur J Cancer 34:2000–2009CrossRefPubMed

45.

Siewert C, Oellinger H, Sherif HK, Blohmer JU, Hadijuana J, Felix R (1997) Is there a correlation in breast carcinomas between tumor size and number of tumor vessels detected by gadolinium-enhanced magnetic resonance mammography? MAGMA 5:29–31CrossRefPubMed

46.

Mann RM, Hoogeveen YL, Blickman JG, Boetes C (2008) MRI compared to conventional diagnostic work-up in the detection and evaluation of invasive lobular carcinoma of the breast: a review of existing literature. Breast Cancer Res Treat 107:1–14. doi:10.1007/s10549-007-9528-5 CrossRefPubMed

47.

Gibbs P, Liney GP, Lowry M, Kneeshaw PJ, Turnbull LW (2004) Differentiation of benign and malignant sub-1 cm breast lesions using dynamic contrast enhanced MRI. Breast 13:115–121. doi:10.1016/j.breast.2003.10.002 CrossRefPubMed

48.

Kuhl CK, Schrading S, Bieling HB, Wardelmann E, Leutner CC, Koenig R, Kuhn W, Schild HH (2007) MRI for diagnosis of pure ductal carcinoma in situ: a prospective observational study. Lancet 370:485–492. doi:10.1016/S0140-6736(07)61232-X CrossRefPubMed

Title: The contralateral synchronous breast carcinoma: a comparison of histology, localization, and magnetic resonance imaging characteristics with the primary index cancer
Authors: Diane M. Renz
Joachim Böttcher
Pascal A. T. Baltzer
Matthias Dietzel
Tibor Vag
Mieczyslaw Gajda
Oumar Camara
Ingo B. Runnebaum
Werner A. Kaiser
Publication date: 01-04-2010
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 2/2010
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-009-0718-1

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2010

Adjuvant therapy of triple negative breast cancer

Association between HER2, TOP2A, and response to anthracycline-based preoperative chemotherapy in high-risk primary breast cancer

Phosphatidylinositol-3-kinase and AKT1 mutations occur early in breast carcinoma

Comments on “Computer-aided detection in full-field digital mammography in a clinical population: performance of radiologist and technologists”

A randomized, placebo-controlled trial (NCIC CTG MAP1) examining the effects of letrozole on mammographic breast density and other end organs in postmenopausal women

DNA methylation of polycomb group target genes in cores taken from breast cancer centre and periphery

Keynote webinar | Spotlight on antibody–drug conjugates in cancer